NCT02186925

Brief Summary

Identifying clinical factors such as medication, background diseases and blood tests that effect the course of disease in cancer patients can help physicians to better decide on the patient's treatment plan. The study seeks to identify and analyze relevant clinical factors that effect the course of the disease and the results of treatment in patients with cancers of the prostate, bladder and kidney.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 2, 2014

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 10, 2014

Completed
22 days until next milestone

Study Start

First participant enrolled

August 1, 2014

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2019

Completed
6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2025

Completed
Last Updated

April 21, 2015

Status Verified

July 1, 2014

Enrollment Period

5 years

First QC Date

July 2, 2014

Last Update Submit

April 20, 2015

Conditions

Kidney CancerProstate CancerBladder Cancer

Keywords

Kidney CancerProstate CancerBladder Cancer

Outcome Measures

Primary Outcomes (1)

  • Progression Free Survival

    Univariate analysis will be used to assess the effects of clinical factors on progression free survival.

    5 years

Secondary Outcomes (1)

  • Patient overall survival

    5 years

Study Arms (1)

Bladder, Kidney and Prostate Cancer Patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients suffering from kidney, bladder or prostate cancer who are being treated at the Meir Medical Center.

You may qualify if:

  • All patients with prostate, bladder or kidney cancer that are being treated at the Meir Medical Center and are over 18 years of age.

You may not qualify if:

  • Patients under the age of 18

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Meir Medical Center

Kvar Saba, 4428164, Israel

RECRUITING

MeSH Terms

Conditions

Kidney NeoplasmsProstatic NeoplasmsUrinary Bladder Neoplasms

Condition Hierarchy (Ancestors)

Urologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital DiseasesGenital Neoplasms, MaleGenital Diseases, MaleGenital DiseasesProstatic DiseasesUrinary Bladder Diseases

Study Officials

  • Daneil Kejzman, MD

    Meir Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Daniel Kejzman, MD

CONTACT

00972-9747-1606daniel.kejzman@clalit.org.il

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 2, 2014

First Posted

July 10, 2014

Study Start

August 1, 2014

Primary Completion

August 1, 2019

Study Completion

August 1, 2025

Last Updated

April 21, 2015

Record last verified: 2014-07

Locations

IL(1)